SUMMARY
Erythropoietin is a 30.4 kDa glycoprotein produced by the kidney, which is mostly known for its physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence, however, suggests that erythropoietin has additional organ protective effects, which may specifically be useful in protecting the brain and kidneys from injury. Experimental evidence suggests that these protective mechanisms are multi-factorial in nature and may include inhibition of apoptotic cell death, stimulation of cellular regeneration, inhibition of deleterious pathways and promotion of recovery.
In this article we review the physiology of erythropoietin, assess previous work that supports the role of erythropoietin as a general tissue protective agent and explain the mechanisms by which it may achieve this tissue protective effect. We then focus on specific laboratory and clinical data that suggest that erythropoietin has a strong brain protective and kidney protective effect. In addition, we comment on the implications of these studies for clinicians at the bedside and for researchers designing controlled trials to further elucidate the true clinical utility of erythropoietin as a neuroprotective and nephroprotective agent.
Finally, we describe EPO-TBI, a double-blinded multi-centre randomised controlled trial involving the authors that is being conducted to investigate the organ protective effects of erythropoietin on the brain, and also assesses its effect on the kidneys. chains appear to be important for the biosynthesis and secretion of EPO. They are thought to enhance stability in the blood and to limit hepatic clearance, thus facilitating the systemic transit of EPO from the kidney (main production site of EPO) to target cells in the bone marrow 9 .
The polypeptide skeleton of the human EPO molecule has a constant amino acid sequence; however, the carbohydrate side-chains are heterogenic in sugar content and structure. The variable nature of the sialic acid content gives rise to EPO isoforms with differences in charge. As the number of sialic acid groups on the carbohydrate portion of EPO increase, so does its serum halflife (Table 1) , while receptor-binding capacity decreases [10] [11] [12] [13] . It is important, however, to note that clearance appears to have a stronger influence on in vivo activity than receptor-binding affinity.
Each EPO molecule has two EPO receptor (EPOR) binding sites, located on opposite faces of the molecule. There are two affinities of the EPOR for EPO in solution; one of high (~1 nM) and one of low affinity (~1 microM), perhaps reflecting two non-equivalent receptor binding sites on each EPO molecule 14 .
Physiological stimuli for erythropoietin production/ release
Approximately 90% of systemic EPO in adults is produced by peritubular interstitial fibroblasts in the renal cortex and outer medulla of the kidney. Most of the remaining production comes from hepatocytes in the liver, with some expression in the brain, spleen, lungs, testes and bone marrow 15 . A feedback mechanism involving oxygen delivery to the tissues appears to regulate EPO production 16 . Hypoxiainducible factor regulates transcription of the EPO gene in the kidney and liver which determines EPO synthesis. This process is dependent on local oxygen tension. Hypoxia-inducible factor is continually transcribed at the messenger riboneucleic acid level but, at the protein level, it is only stable in hypoxic cells. Hypoxia-inducible factor is quickly destroyed by well-oxygenated cells through ubiquitylation (tagging for degradation in the proteasome) by the von Hippel-Landau tumour suppressor protein.
However when oxygen delivery decreases, the von Hippel-Landau tumour suppressor protein ceases its proteolysis of hypoxia-inducible factor, increasing the levels of hypoxia-inducible factor which subsequently increases EPO production 15, 17 .
Structure of erythropoietin receptors
The EPOR is a 66kD membrane glycoprotein typically consisting of 484-amino acids and two peptide chains. It belongs to a large cytokine and growth factor receptor family, which includes IL-3, -4, -6 receptors, granulocyte macrophage colony stimulating factor receptor and the growth hormone receptor, and has some common signalling mechanisms 3 . The EPOR has a single transmembrane domain, an extracellular domain composed of two parts and an intracellular domain 3 . Binding studies have demonstrated that the EPOR has different affinities for EPO with perhaps an accessory component of the EPOR that increases the binding 14 .
It is thought that EPOR isoforms with higher affinity for EPO binding may be responsible for the erythropoietic effects of EPO, while isoforms with a lower affinity for EPO binding may have nonerythropoietic effects such as tissue protection 18 . The cytoplasmic domains of the EPOR contain a number of phosphotyrosines that are phosphorylated by the activation of a member of the Janus-type protein tyrosine kinase family (JAK2), which is bound to the common beta subunit of the EPOR 19 . In addition to activating the mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) pathway ( Figure 114 ), phosphotyrosines also serve as docking sites for signal transducer and activators of transcription (STAT) such as STAT5 14 . These pathways are further described in "Postreceptor (intracellular) effects of erythropoietin" below. Dephosphorylation of JAK can be induced by phosphatase with the consequent internalisation and degradation of the EPO/EPOR complex which marks the end of EPO activity. This prevents overactivation that may lead to excessive erythrocytosis 20 .
The erythropoiesis stimulating effects of erythropoietin
The principal physiological function of EPO is red blood cell production, which results from a tightly controlled proliferation and differentiation pathway 21 . Early haematopoietic progenitor cells differentiate into burst-forming unit-erythroid cells on which EPORs first appear. However, EPO is not required at this stage. Burst-forming uniterythroid cells differentiate into colony-forming unit-erythroid cells, dependent on EPO for survival, with a corresponding increase in EPOR expression 21 .
Continuous stimulation with EPO triggers the differentiation of colony-forming unit-erythroid cells into erythroblasts, which lose their nuclei to form reticulocytes. After a few days reticulocytes lose reticulin and become erythrocytes (red blood cells). Reticulocytes and erythrocytes stop expressing EPOR and cease being responsive to EPO 21 . The steady-state lag time between effectsite EPO stimulation and reticulocyte appearance in the human systemic circulation was estimated at 10.8 hours 22 and the steady-state reticulocyte residence time reported in humans is one day, which increases two-to three-fold during stress erythropoiesis 23 . FigurE 1 : The main pathways of erythropoietin (EPO). The intracellular domain of the erythropoietin receptor contains phosphotyrosines that are phosphorylated by activation of a member of the Janus-type protein tyrosine kinase family (JAK2), which is bound to the beta subunit of the EPO receptor. These phosphotyrosines then serve as docking sites for Signal transducer and activator of transcription 5 (STAT5) and activate the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) pathway 14 . Akt stimulates IkappaB kinase (IKK) to phosphorylate which phosphorylates the inhibitory IkB protein that then dissociates from nuclear factor-kappaB (NF-kB) resulting in its activation.
Cell wall phosphorylation phosphorylation
EPO-binding to EPORs on erythroid progenitor cells leads to activation of the JAK2-STAT5 signalling pathway and phosphorylation of PI3K and Akt 24 (Figure 1 ). Akt-mediated phosphorylation of Bad (a pro-apoptotic member of the B-cell lymphoma 2 protein family) in the Bad-B-cell lymphoma-extra large (Bcl-x L ) complex releases the antiapoptotic protein Bcl-x L (B-cell lymphoma-extra large), which suppresses erythroid progenitor cell apoptosis 25 . Akt is also involved in several pathways that promote cell survival and anti-apoptotic effects through inhibition of forkhead transcription factor (FOXO3a), inactivation of glycogen synthase kinase 3β (GSK3β), induction of x-chromosome-linked inhibitor of apoptotic protein (XIAP), inactivation of caspases, and prevention of cytochrome C release ( Figure 2 19, 26, 27 ). These effects not only enhance the erythropoietic properties of EPO but appear to be important in the protection of other cell types as well and may contribute to the reported neuronal and renal protective effects 24 .
PLEIOTROPIC EFFECTS OF ERYTHROPOIETIN
The tissue protective effects of EPO may be elicited through the EPOR homodimer via JAK2-STAT5 activation and mediation of apoptosis. However, the interaction and contribution of the various downstream cellular signalling pathways may differ for each different cell type. Alternatively or additionally, tissue protection may be mediated by a second EPOR isoform; a heterodimer composed 19, 27 . Erythropoietin can phosphorylate extracellular signal-related kinases (ERK), one of three groups of mitogen-activated protein kinase (MAPK). The ERK pathway (ERK 1 and 2) is associated with apoptotic regulation and can be cytoprotective 26 . Akt promotes cell survival and anti-apoptotic effects by 1) inhibiting forkhead transcription factor (FOXO3a), a trigger for apoptosis; 2) inactivating glycogen synthase kinase 3β (GSK3β), thus preventing cell injury; 3) reducing the activity of pro-apoptotic proteins Bad and B-cell lymphoma 2-associated X protein (Bax); 4) increasing the activity of anti-apoptotic protein B-cell lymphoma 2 (Bcl-2); 5) maintaining mitochondrial membrane potential, thus preventing cytochrome C (Cyto-C) release. Nuclear factor-kappaB (NF-kB) prevents apoptosis by 1) inducing expression of the inhibitors of apoptotic protein (IAP) C-IAP 1 and 2, and the x-chromosome-linked IAP (XIAP), which can inhibit active caspase 3, 7 and 9; and inhibit caspase 8 activation (C-IAP 1 and 2); 2) promoting induction of Growth arrest and DNA damage protein (Gadd45β) by TNF-α, which is associated with cell cycle and DNA repair, and suppression of apoptosis; 3) by activating Bcl-xL. EPO induces heat shock protein 70 (HSP70) which inhibits apoptosis inducing factor (AIF) moving into the nucleus, thus avoiding DNA fragmentation and apoptosis. HSP70 also prevents apoptotic protease-activating factor-1 (Apaf-1)/cytochrome C (Cyto-C) binding; a complex involved in pro-apoptotic caspase activation. PKB=protein kinase B.
of an EPOR monomer and the cytokine receptor, common beta subunit. This signal-transducing subunit is also common to the granulocyte-macrophage colony stimulating factor and the IL-3 and IL-5 receptors 28, 29 . Carbamylated EPO (CEPO) does not bind to the classical EPOR isoform, and is devoid of classic haematopoietic activity 5, 30 (Table 1 ), yet has been shown to provide tissue protection in the brain, heart 31 and kidney 30 , supporting the existence of a heteroreceptor EPO isoform, which mediates tissue protection.
Carbamylated erythropoietin and tissue protection
The administration of CEPO, provides renal tissue-protective effects. In an ischaemia-reperfusion rat model, CEPO markedly reduced apoptosis and increased tubular epithelial cell proliferation. Moreover, CEPO was more protective against ischaemia-reperfusion injury to tubular epithelial cells than EPO in this study 4 . In an in vitro model developed by the same team, CEPO promoted more capillary formation than EPO and also appeared to protect the kidneys from ischaemia-reperfusion injury by promotion of angiogenesis 32 . This protective effect requires mitogenesis, and endothelial progenitor cell differentiation, proliferation and migration. The anti-apoptotic, cell proliferative, angiogenesis-promoting properties of CEPO may indicate involvement of the following signalling pathways: JAK2-STAT5, PI3K/Akt and downstream anti-apoptotic pathways, and mitogen-activated protein kinase. Whether different conformations of the EPOR activate different intracellular pathways or whether the single EPOR chain (in the case of CEPO) dimerises with other membrane proteins to provide the protective effect is currently not known 18 . Different classes of EPOR with respect to affinity for EPO-binding have also been described: high affinity EPOR appear to mediate the haematopoietic effects and low affinity receptors may be principally involved in tissue protection by EPO 18 .
It is clear that the relationship of EPO with its receptor is extremely complex. Therefore further investigation is required to fully understand the EPOR heterodimer isoform, and the mechanisms and pathways involved in its tissue protective activity. These findings could inform the future development of tissue-protective cytokines.
Post-receptor (intracellular) effects of erythropoietin
There are a number of common pathways through which EPO exerts its erythropoietic effects that also appear to confer tissue protection. As mentioned, it is uncertain whether the pathways for tissueprotection are activated by EPOR homodimers or heterodimers, both, or another receptor conformation 18 . EPO 'classically' binds to two EPORs which become joined as a homodimer and change. This activates JAK2, which is bound to the common beta subunit of the EPOR 19 , and leads to phosphorylation of tyrosine residues of the EPOR, which activates a number of signalling pathways discussed below (Figures 1 and 2) .
Signal transducer and activators of transcription 5 EPO classically signals through the STAT5 pathway. The STAT proteins are direct substrates of Janus kinases (JAK); activation of JAK results in tyrosine phosphorylation of the STATs (Figures 1  and 2 ). Activation of JAK2 also leads to phosphorylation of the PI3K and subsequent phosphorylation of Akt (also known as protein kinase B) ( Figure 1 ).
Akt
Akt (also called protein kinase B) is important because it is the principal component in a variety of pathways that promote cell survival and antiapoptotic effects ( Figure 2 ). It is involved in inactivating caspases which mediate apoptosis, mitochondrial dysfunction and subsequent release of cytochrome C 27 , leading to cell injury and genomic DNA degradation. Cytochrome C binds to apoptotic protease-activating factor-1 which activates proapoptotic caspase pathways and results in cell injury and death 27 . Akt reduces caspase activation by increasing the activity of B-cell lymphoma 2 and Bcl-x L which, in turn, prevent B-cell lymphoma 2-associated X protein translocation to the mitochondria, maintain mitochondrial membrane potential and prevent cytochrome C release from the mitochondria 19 . EPO's ability to maintain cellular integrity and prevent inflammatory apoptosis is closely linked to maintenance of mitochondrial membrane potential; modulation of apoptotic proteaseactivating factor-1; inhibition of cytochrome C release and inhibition of caspase 1, 3, 8 and 9 activation.
Recent data also indicate that PI3K-regulated serum and glucocorticoid-regulated kinase-1 may contribute to the mediation of EPO's anti-apoptotic effects and possibly renal protective effects 33 .
Mitogen-activated protein kinase
The phosphorylation of mitogen-activated protein kinases appears to also contribute to the cell protection which EPO confers ( Figure 2 ).
Protein kinase C
Protein kinase C is also involved in the signal transduction pathways of EPO and inhibition of apoptosis and cell survival. It regulates the EPO-induced erythroid proliferation and differentiation 34 . Indeed, inhibition of protein kinase C activity interferes with phosphorylation of the EPOR which suggests that protein kinase C may be an upstream modulator of the EPOR 27 .
Calcium
EPO may be involved in modulation of cellular calcium homeostasis given that classical protein kinase C isoenzymes depend on calcium for activity 35 . EPO can elicit a prompt rise in intracellular free calcium in bone marrow, stimulate calcium channel activity and enhance intracellular calcium concentration of neuronal cells [35] [36] [37] . This suggests that EPO influences calcium homeostasis by increasing calcium influx 38 . A quick, transient increase in calcium by EPO may be required for cytoprotection during excitotoxicity, since a reduction of intracellular calcium can cancel the protective effect of EPO during glutamate administration 39 . EPO may enhance the function and viability of neurons through a calcium mechanism 37,40 .
Nuclear factor-kappaB
Nuclear factor-kappaB (NF-kB), a mediator of inflammatory and cytokine response is also implicated in EPO signalling. The expression and cytoprotection of EPO partly depend on Akt and subsequent NF-kB activation (Figures 1 and 2 ). NF-kB plays a role in the release of EPO during hypoxia-inducible factor-1 induction; Akt can increase NF-kB and hypoxia-inducible factor-1 activation with resultant increase in EPO expression 41 .
Heat shock protein 70
Induction of heat shock protein 70 by EPO is related to renal protection in ischaemic kidneys 42 . Heat shock protein 70 prevents apoptosis a) by inhibiting movement of apoptosis inducing factor to the nucleus 43 and b) by preventing apoptotic proteaseactivating factor-1/cytochrome C binding in the cytosol 44 (Figure 2 ).
Potential new tissue protective mechanisms
There are other mechanisms by which EPO may confer cytoprotection. It has recently been demonstrated that local nitric oxide bioavailability increases when EPO activates endothelial nitric oxide synthase and this effect on the endothelium may be critical for the renal tissue protective effects of EPO. EPO is an extremely potent stimulator of endothelial progenitor cells, whose function is partly dependent on nitric oxide bioavailability. Endothelial progenitor cells appear to be involved in endothelial recovery after injury and the formation of new blood vessels in ischaemic areas 18 . In the kidney, AKI triggers apoptosis, inducing an inflammatory response. EPO limits these negative effects in part by stimulating vascular repair and by mobilising endothelial progenitor cells and increasing tubular cell proliferation 28 . These findings suggest that EPO may exert protective effect via an interaction with the microvasculature.
Angiogenesis and EPO's renal protective effects may also be influenced by vascular endothelial growth factor (VEGF). In a number of studies, the presence of VEGF appears to be associated with tissue protection [45] [46] [47] . EPO was the first described hypoxia-inducible factor target gene but many more have been discovered including VEGF which has additional potential to provide renal protection 28 . Nakano and colleagues found that the vascular EPO/EPOR system promoted post-ischaemic angiogenesis by upregulating the VEGF/VEGF receptor system, both directly by promoting neovascularisation and indirectly by mobilising endothelial progenitor cells and bone marrow-derived proangiogenic cells 48 . It appears that angiogenesis is impaired and blood vessels are less responsive to VEGF in the absence of EPOR.
In animal studies, preconditioning of the hypoxiainducible factor system using short episodes of ischaemia has been found to protect the kidney from ischaemic and toxic injury. Hypoxia-inducible factor is capable of inducing a range of protective gene products including glucose transporters and heme oxygenase-1 with renal protective potential. Comparison of the protective capacities of EPO and hypoxia-inducible factor activation in the kidneys may be worthwhile 28 . Moreover, it is possible that some effects of EPO such as the promotion of angiogenesis may be responsible for some of the benefit provided by ischaemic preconditioning. The tissue protective or 'pleiotropic' effects of EPO beyond erythropoiesis have been shown in the brain, heart and kidney in many animal and some clinical studies.
Neurological protection
Traumatic brain injury and the potential protective effect of erythropoietin Brain injury, particularly as a result of trauma, is a leading cause of mortality and long-term disability, particularly affecting young people. It is associated with significant human and financial costs. Complementary to measures to prevent injury, treatment can be directed at decreasing morbidity after primary injury 49 . Extensive research shows that, after brain trauma (primary injury), several biochemical pathways are activated, leading to secondary brain injury 50 . These pathways include inflammation, oxidative stress, increased vascular permeability and excitotoxic mechanisms (release of chemicals toxic to brain cells) 50 . Secondary injury greatly increases brain cell death, stroke size and overall brain injury 51 . Despite intense investigation, no specific treatment has conclusively been shown to attenuate secondary brain injury, and current management of traumatic brain injury (TBI) is supportive, seeking to prevent or rapidly treat complications which worsen secondary injury 52, 53 . It is therefore a priority to investigate promising therapies for traumatic or acute brain injury and EPO is one such intervention.
Mechanisms
Human neurons, astrocytes and microglial cells produce EPO and express EPOR 54 . The increase in production and secretion of EPO and enhanced expression of the EPOR in the human central nervous system in response to oxygen deficiency suggests a possible physiological role for EPO to attenuate secondary brain injury 27 . The receptor complex mediating the neuroprotective effects of EPO may be associated with the common beta receptor subunit, CD131. Increasing evidence suggests that EPOR activation after EPO binding inhibits neuronal apoptosis 55, 56 . EPO-EPOR binding may induce JAK2 activation with phosphorylation of the inhibitor of NF-kB, leading to transcription of neuro-protective genes 57 (Figure 2 ). In addition, EPO seems to prevent neurological apoptosis through an Akt-dependent mechanism 58 . Amongst a number of cell-survival promotion pathways, Akt blocks cell apoptosis by inhibiting glycogen synthase kinase 3β 59 (Figure 2 ). Furthermore, an in vitro study indicated that EPO attenuated glutamate excitotoxicity when given after its induction, and promoted nerve terminal sprouting in motor neurons by direct effect involving the JAK2 pathway 60 .
EPO's neuroprotective mechanisms could also include activation of calcium channels to protect from glutamate toxicity, antioxidant enzyme production and neo-angiogenesis that improves blood flow and oxygenation in border zones of ischaemic areas 61 . EPO also blocks free radicals, normalises cerebral blood flow, affects neuro-transmitter release (preventing excitotoxicity) and has anti-inflammatory effects, thus playing a crucial role in neuroprotection of the central and peripheral nervous system 62 . It is therefore clear that EPO modulates a number of key pathways which could reduce neural injury and provide protective effects.
Animal studies
In animal models, EPO has been shown to decrease cerebral infarct volume, oedema and neuronal apoptosis, while neuronal survival and cerebral function increased [63] [64] [65] . Following experimental subarachnoid haemorrhage, EPO was shown to reduce neuronal death and vasoconstriction and improve functional recovery and cerebral blood flow autoregulation [63] [64] [65] . EPO's potential to prevent cortical injury has been investigated in spinal cord models, the ocular system and the peripheral nervous system in animals with promising results [66] [67] [68] [69] [70] . Importantly, administration of EPO up to 24 hours after a traumatic brain injury has been shown to be protective and to improve functional neurological outcomes in rats 71 . These results suggest that EPO not only attenuates gross anatomical injury but that it may also improve functional outcomes when administered many hours after the primary insult in animal models of brain injury.
Clinical trials
In humans, EPO dramatically improved functional neurological outcomes in a randomised controlled trial when administered to patients with subarachnoid haemorrhage 72 . Furthermore, in a double-blind proof-of-concept study, high dose EPO improved clinical outcome of patients at one month after acute ischaemic stroke and displayed a trend for reduction in infarct size. Moreover, EPO appeared to reduce neurocognitive dysfunction at two months after coronary artery bypass graft surgery and was considered safe to use in a double-blind Canadian randomised control trial 73 . In chronic neurological disease EPO may also provide benefit. High-dose EPO appeared to improve cognitive performance in a small study of schizophrenic men with cognitive deficit, compared to placebo-treated patients 74 . A small open label exploratory study of high-dose EPO for patients with chronic progressive multiple sclerosis also suggested potential benefit 75 . EPO has the potential to provide benefit for neurological dysfunction in numerous settings.
A large multicentre intensive care unit (ICU) randomised controlled trial 53 found that EPO significantly decreased 29-day mortality compared to placebo (3.5% vs 6.6%) in a pre-planned subgroup analysis of trauma patients (many with traumatic brain injury). This occurred despite a lack of effect on transfusion requirement. However, an increase in thrombotic events was noted. In a recent German double-blind randomised controlled trial of EPO in acute ischaemic stroke, systemic thrombolysis (rtPA) was concurrently administered with EPO in 76 . Contrary to existing clinical evidence 77 from a small single-centre study, this trial showed a negative effect, which may be related to the concurrent use of thrombolysis and/or factors related to the multi-centre nature of this trial. Notably, intracerebral haemorrhage was the main cause of death, and stroke severity was higher in those who died in the EPO group. Furthermore, pre-clinical combination therapy safety studies had not been performed 78 . Of note, it is stated that one of the authors of this study holds a patent on the use of EPO for the treatment of cerebral ischaemia 76 . There is substantial experimental evidence, a plausible biological rationale and supportive clinical evidence from clinical trials to suggest a possible beneficial effect of EPO in acute and chronic brain injury. In addition, a recent small case controlled study suggests that EPO used in conjunction with hypothermia may increase survival and improve neurological outcomes 79 . However, as these clinical studies suggest, EPO treatment may also result in clinically important side-effects.
Renal protection Animal and in vitro studies
EPORs have been found in both vascular and non-vascular renal tissue 80 . Many animal studies have shown that EPO administration protects kidney tissue from damage and improves renal function in ischaemia-reperfusion and contrast-induced injury models of AKI (Tables 2 and 3 4, 8, 24, 32, 42, 46, 47, ). These investigations invariably found that EPO reduced kidney dysfunction by decreasing apoptosis. It has also been shown that different intracellular 'survival' pathways in the kidney such as the PI3K/Akt pathway are activated by EPO 103, 104 . Furthermore, in a recent in vitro study 24 , EPO was shown to reduce cisplatin-induced apoptosis in human proximal tubule epithelial cells, while phosphorylation of STAT5 and Akt increased. Involvement of the JAK2-STAT5 pathway has also been implicated in cell protection 8, 24 . STAT5 activation can modulate proliferation and protect against cell apoptosis. In addition, EPO has been shown to reduce the expression of pro-inflammatory mediators, TNF-alpha and IL-2, in ischaemia-reperfusion renal injury and reverse the effect of endotoxin on the anti-oxidant, renal superoxide dismutase 94 . These anti-inflammatory properties of EPO also suggest involvement of the NF-kB pathway in its kidney protection.
Erythropoietin in acute kidney injury AKI as classified by the RIFLE criteria (an extensively used and validated classification system for renal function) is common in the ICU and occurs in approximately 36% of critically ill patients 105, 106 . AKI 2004 81 Rats Haemorrhagic shock and endotoxic shock EPO 300 U/kg IV pre resuscitation ↓renal dysfunction in haemorrhagic but not endotoxic shock is independently associated with increased mortality and with prolonged length of stay. It escalates both the human and financial costs of care. Therefore, it seems desirable to investigate treatments with potential to ameliorate or prevent AKI. Some injury pathways for AKI in the critically ill include exposure to endogenous and exogenous toxins, metabolic factors, ischaemia and reperfusion insults, neurohormonal activation, inflammation and oxidative stress. Of these, ischaemia-reperfusion may be the most common. EPO can prevent or reduce injury and assist renal repair and recovery through limitation of apoptosis, promotion of neovascularisation, anti-inflammatory action and tissue regeneration.
Investigation of potential treatments for AKI has had limited success to date. However, from the results of animal and some limited preliminary human studies, therapeutic use of EPO seems promising for those 'at risk' for AKI 8, 86, 96, 107 .
Clinical trials of erythropoietin in acute kidney injury
One randomised clinical pilot trial of preoperative EPO/placebo in 71 patients undergoing elective coronary artery bypass graft surgery showed renal protective results 107 (Table 4 107, 108 ). EPO 300 µ/kg intravenous given immediately preoperatively seemed to reduce the incidence of AKI, (8% EPO vs 29% placebo, P=0.035); and improved postoperative renal function as indicated by a smaller increase in SCr (%SCr↑ at 24 hours: EPO 1±3, placebo 15±7, P=0.04) and a smaller decline in estimated glomerular filtration rate (% estimated glomerular filtration rate ↓ at 24 hours: EPO 3±3, placebo -5±4, P=0.04) postoperatively (Table 4) . A more recent and slightly larger (n=162) study assessed EPO's effect in ICU patients at risk for AKI (defined by a cut-off value of two proximal tubular enzymes in urine: γ-glutamyl transpeptidase and alkaline phosphatase) ( Table 4 ). EPO 500 µ/kg intravenous was given after a high γ-glutamyl transpeptidase ×alkaline phosphatase product was detected and again 24 hours later. The primary outcome was the average percent SCr increase from baseline over four to seven days. This trial found no renal protective effect of EPO as determined by the average percent SCr increase from baseline over four to seven days. Table 4 compares the 'coronary artery bypass graft' and 'EARLY ARF' EPO trials. The reasons for these contradictory findings may be related to the differences in design and methods used.
Potential risks of erythropoietin
Pure red cell aplasia Despite the numerous benefits of EPO there are also some risks. Pure red cell aplasia is a rare adverse event characterised by anaemia, low reticulocyte count, absence of erythroblasts, resistance to EPO and neutralising antibodies against EPO 109, 110 . Only three cases were reported in EPO patients from 1988 to 1998, after which incidence increased to a peak in 2001. This was attributed to a number of factors that were subsequently addressed. Since the introduction of Teflon-coated plungers (2003) , and changes to EPO formulation and the regulation of EPO administration (2002 to 2004), there have been only six reported cases of pure red cell aplasia, converting it once again into an extremely rare occurrence.
Cancer patients
EPO administration in patients with cancer, given to reduce chemotherapy or radiotherapy induced anemia, has been associated with increased mortality and enhanced tumour growth 17, 111 . The underlying mechanisms remain uncertain, but EPO may serve as a growth factor to cancer cells and may promote 
Thrombosis
Recent studies and clinical trials have found an increased rate of thrombosis with EPO 53, 112, 113 which has mainly been observed in patient groups with higher than conventional levels of haemoglobin (>120 g/l) 113 . Putative mechanisms are increased blood viscosity, increased platelet count and reactivity, decreased protein C and S plasma levels, enhanced thrombin generation and factor VIII antigen plasma levels. Exclusion of patients with haemoglobin >120 g/l from clinical trials of EPO minimises the risk for thrombosis 113 . Nonetheless, systematic assessment for thrombosis should be performed in any EPO trials of critically ill patients as they have an increased risk for thrombosis.
Hypertension
Hypertension occurs in about 30% of patients receiving long-term EPO treatment 3 . This was partly attributed in the past to the rise in haematocrit, but now appears to involve increased endothelin release, upregulation of tissue renin and angiotensin production, changes in the balance of vasoactive substances (prostaglandin/prostacyclin/ thromboxane), and an elevation of calcium by EPO (at least in chronic kidney disease) that impairs the vasodilating action of nitric oxide 27 . It is advisable that patients with uncontrolled hypertension do not participate in trials of EPO in AKI.
Carbamylated EPO, a cytoprotective, nonerythropoietic derivative of EPO (Table 1) , may not exhibit the same risks as EPO and holds great interest as a future tissue-protective therapy. However, it requires further experimental testing before it can be safely evaluated in clinical trials.
The EPO-TBI trial and EPO-AKI substudy
EPO-TBI, a randomised, double-blind, controlled trial of EPO in ICU patients with TBI in Australia, New Zealand and Saudi Arabia, has recently commenced recruitment (ACTRN12609000827235) at the Alfred and Royal Melbourne hospitals in Victoria. The trial will soon roll out to a total of 19 sites. EPO-TBI is endorsed by the Australian and New Zealand Clinical Trials Group and has National Health and Medical Research Council and Victorian Neurotrauma Initiative funding. With a cohort of 606 patients, it will be the largest randomised controlled trial of EPO in patients with TBI ever performed. Furthermore, it is one of the largest TBI trials currently being conducted. Participants are moderate and severe TBI patients admitted to ICU with a GCS ≤12, aged between 15 and 65 years, with a haemoglobin <120 g/l, within 24 hours of injury and expected to stay ≥48 hours. Patients will be randomised to receive either EPO 40,000 IU subcutaneously or placebo in a 1:1 ratio, weekly for up to three weeks while in ICU. Pharmaceutical and mechanical venous thrombo-embolism prophylaxis will be prescribed if not contraindicated, and compression Doppler ultrasound examinations to monitor patients for the development of proximal deep vein thrombosis will be performed prior to or within 48 hours of the first EPO/placebo dose, then twice in each week following each dose. The primary outcome is the proportion of unfavourable neurological outcomes at six months: defined as severe disability (Glasgow outcome scale, extended=2 to 4) or death (Glasgow outcome scale, extended=1).
'EPO-AKI' and 'EPO-Biomarkers' comprise the Intensive Care Foundation-funded renal sub-study of the EPO-TBI trial. This sub-study assesses the effect of EPO on the development of acute kidney injury and the response to treatment using multiple renal biomarkers with different time profiles. All of these biomarkers have been extensively investigated and patterns in response to injury are known. Having recently sustained a timed physical injury and with a moderate incidence of AKI 114, 115 , this homogeneous cohort lends itself to such a study. AKI will be classified using methods based on the RIFLE criteria; a classification system used extensively and validated to classify renal function in several populations with studies cumulatively involving over 250,000 subjects. Baseline renal function will be taken from a consistent source for all patients. With a cohort of 606 patients, this will also be the largest study of EPO to protect against AKI ever performed, increasing the probability of detecting a treatment effect. Furthermore, it will be the first EPO trial to incorporate active risk assessment for thrombotic episodes. Weekly intervals separate the doses of EPO (up to three) in this trial to allow time for clearance and avoid excessively high levels of EPO. In addition, patients with a known malignancy and/ or uncontrolled hypertension will be excluded, thus minimising risk to patients. The EPO-TBI trial provides a unique opportunity to clarify the potential benefit of EPO as a brain protective and kidney protective agent. This trial may also provide valuable insight into the mechanisms of EPO in AKI and pave the way for further dedicated large scale trials of EPO in AKI.
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